Magle Chemoswed congratulates Oncopeptides

Magle Chemoswed congratulates everyone at Oncopeptides for receiving FDA approval of PEPAXTO®. We are proud to have been chosen by Oncopeptides as a development and manufacturing partner for the active pharmaceutical substance. It has been a great pleasure to support Oncopeptides and supply development and manufacturing services around the active pharmaceutical substance through all phases of the development and clinical stages.

“Working with Oncopeptides as a partner in development and manufacturing has been a real honour, and we look forward to further supporting Oncopeptides in the commercial supply of their active pharmaceutical substance in the future, “ said Fredrik Andersson, Chief Operating Officer of Magle Chemoswed.